Cancer diagnostics.

Design and manufacture accelerator graphical cards for datacenters.

Oxvalue.ai offers a useful new approach for appraising technology, and an important guide for decision-making in technology investment, transfer and commercialisation.

Digital health company focused on neurodegenerative diseases.

Digital CBTe software.

A proprietary multi-omics discovery platform to resolve RNA-centric mechanisms in rare and chronic diseases.

Provides advanced insights on global information operations, data flows, and public understanding of critical issues.

Provides the tools you need to measure, report, and act on nature risks and opportunities, aligned with global regulations and standards.

A US non-profit which aims to provide education and tools for preventing public health crises and pandemics and to strengthen global public health preparedness

Aim to deliver rapid diagnosis of inherited blood disorders, infectious diseases and early-stage cancer in sub-Saharan Africa.

Design oligonucleotide drugs that can activate expression of specific genes using a novel gene regulatory mechanism.

Help customers obtain high-purity metals from their waste or process streams in a simple & highly profitable manor and achieve sustainability goals by removing toxic metals from wastewater.

Revolutionising the production of Fluorochemicals. A highly innovative, cost-effective and sustainable technology that removes the hazards of traditional fluorinating processes and supply chain.

High-speed Vision, LIDAR and IMU tracking/odometry and mapping.

OxCo produces videos in collaboration with researchers, teaches academics how to leverage video technologies, and convenes unique hybrid events.

Platform to promote critical thought on India and British Indians.

To improve the ESG outcomes of publicly traded corporations by enhancing the efficacy of shareholder ownership rights.

Optical neural networks.

To develop and commercialise a rapid non-lab based diagnostic test for viral infections, with the first focus on Covid19.

To discover significantly de-risked novel drug targets for licensing and in-house development.